Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
JSP Pharmaceutical Manufacturing (Thailand) PCL's 3-Year RORE % for the quarter that ended in Mar. 2026 was 217.91%.
BKK:JSP's 3-Year RORE % is ranked better than 95.57% of 1828
companies
in the Consumer Packaged Goods industry
Industry Median: 6.05
vs BKK:JSP: 217.91
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
JSP Pharmaceutical Manufacturing (Thailand) PCL 3-Year RORE % Related Terms
JSP Pharmaceutical Manufacturing (Thailand) PCL 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JSP Pharmaceutical Manufacturing (Thailand) PCL 3-Year RORE % vs Consumer Packaged Goods Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) has a 3-Year RORE % of 217.91 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors. According to the industry distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #81 out of 1828 companies in the Consumer Packaged Goods industry, placing it in the top 4.4%.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL's 3-Year RORE % too high?
JSP Pharmaceutical Manufacturing (Thailand) PCL's current 3-Year RORE % is 217.91. The Consumer Packaged Goods industry median 3-Year RORE % is 6.05. JSP Pharmaceutical Manufacturing (Thailand) PCL's value of 217.91 is 3501.8% above this industry median. Based on the distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #81 out of 1828 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, JSP Pharmaceutical Manufacturing (Thailand) PCL has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JSP Pharmaceutical Manufacturing (Thailand) PCL's 3-Year RORE % compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #81 out of 1828 companies for 3-Year RORE %. This places JSP Pharmaceutical Manufacturing (Thailand) PCL in the top 4% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 6.05. JSP Pharmaceutical Manufacturing (Thailand) PCL's value of 217.91 is 3501.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Consumer Packaged Goods company?
The median 3-Year RORE % among Consumer Packaged Goods companies is 6.05, based on 1,828 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JSP Pharmaceutical Manufacturing (Thailand) PCL's current 3-Year RORE % of 217.91 is 3501.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors. For the Consumer Packaged Goods industry, the median 3-Year RORE % is 6.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JSP Pharmaceutical Manufacturing (Thailand) PCL's current 3-Year RORE % is 217.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL stock overvalued right now?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿3.19, compared to a current price of ฿1.75 — trading 45.1% below its estimated fair value. The current 3-Year RORE % is 217.91 and 3501.8% above the Consumer Packaged Goods industry median of 6.05. JSP Pharmaceutical Manufacturing (Thailand) PCL's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP), the current 3-Year RORE % is 217.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) Overvalued in 2026?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL stock appears to be undervalued.
The current stock price of ฿1.75 is trading 45.1% below its estimated GF Value™ of ฿3.19.
GuruFocus considers JSP Pharmaceutical Manufacturing (Thailand) PCL to be Significantly Undervalued.
Key valuation signals for BKK:JSP:
3-Year RORE %: 217.91
GF Value™: ฿3.19 vs. price of ฿1.75 (45.1% below fair value)
Industry Position: 3501.8% above the Consumer Packaged Goods median (#81 of 1828)
No single metric tells the full story. See the BKK:JSP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JSP Pharmaceutical Manufacturing (Thailand) PCL is engaged in producing modern medicine, traditional medicine, herbal products, dietary supplements, medical supplies, and cleaning alcohol under the client's and the company's own trademarks. Maximum revenue for the company is generated from the sale of dietary supplements. The Group's reportable operating segments are: Manufacture and distribution of products under the company's brand name (Own brands), which generate maximum revenue, Manufacture and distribution of products under customers' brand name (OEM), Manufacture and distribution of hemodialysis solution and related medical supplies; and Service, research and development, and healthcare products training. Geographically, it operates principally in Thailand.
84GF Score
Get the complete analysis for BKK:JSP
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:JSP has been successfully added to your 
